ClinConnect ClinConnect Logo
Search / Trial NCT06889987

Bilateral Ultrasound Guided Intramuscular Quadratus Lumborum Plane Block Versus Bilateral Lateral Quadratus Lumborum Plane Block in Controlling Postoperative Pain in Cancer Patients Undergoing Open Nephrectomy

Launched by NATIONAL CANCER INSTITUTE, EGYPT · Mar 16, 2025

Trial Information

Current as of April 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at two different methods for managing pain after surgery in cancer patients who are having a kidney removed through a procedure called open nephrectomy. Specifically, the study compares two types of injections—one that targets a specific muscle area using ultrasound guidance and another that uses a different approach to block pain. The goal is to find out which method works better in helping patients feel comfortable after their surgery.

To participate in this trial, patients need to be between 18 and 65 years old and have a certain level of health as defined by the American Society of Anesthesiology. They should also have a body weight that falls within a specific range. Patients who are interested should be aware that some may not be eligible if they have certain health issues, are on specific medications, or have a history of chronic pain or drug abuse. Those who join the study can expect to receive either of the two pain management techniques and will be monitored for how well these methods control their pain after surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age from 18 to 65 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status II-III.
  • Body mass index (BMI): (20- 40) kg/m2.
  • Type of surgery: midline incision for unilateral open nephrectomy.
  • Exclusion Criteria:
  • Patient refusal.
  • Age \<18 years or \>65 years
  • BMI \<20 kg/m2 and \> 40 kg/m2
  • Known sensitivity or contraindication to drugs used in the study
  • Contraindication to regional anesthesia, e.g. local infection at the introduction site, pre-existing peripheral neuropathies and coagulopathy.
  • Physical status ASA IV
  • Patients on chronic analgesic therapy (daily morphine ≥30 mg or equivalent dose of other opioids or tramadol or any medication for neuropathic pain)
  • Patients with a history of drug abuse
  • Patients with neuropsychiatric diseases; patients with a history of chronic pain syndromes that may enhance sensitivity to pain, for example, fibromyalgia
  • All patients who are going to have severe intra- or post-operative bleeding or will require postoperative mechanical ventilation are also excluded from the study.

About National Cancer Institute, Egypt

The National Cancer Institute, Egypt, is a premier research institution dedicated to advancing cancer prevention, treatment, and care through innovative clinical trials and comprehensive research initiatives. As a leading sponsor of clinical studies, the Institute focuses on understanding cancer biology, improving therapeutic strategies, and enhancing patient outcomes. With a commitment to scientific excellence and collaboration, the National Cancer Institute plays a crucial role in addressing the cancer burden in Egypt and the broader region, fostering partnerships with local and international researchers to drive forward the frontiers of oncology.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported